Another front in COVID-19's perfect storm

In this issue of Blood, Althaus et al identify circulating procoagulant platelets as a novel biomarker of COVID-19 disease severity and present provocative in vitro findings demonstrating that antibodies induced in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can initiate procoagulant platelet formation.(1)

Automated summary

The study identifies circulating procoagulant platelets as a novel biomarker of COVID-19 disease severity and demonstrates that antibodies induced in response to SARS-CoV-2 can initiate procoagulant platelet formation.